Clyde Biosciences

Clyde Biosciences Autumn Business Update

Posted on Leave a commentPosted in news

Clyde Biosciences Autumn Business Update Highlights CiPA 28 study finished and data submitted weeks ahead of schedule New CellOPTIQ®-X contractility assay launched New Heart Failure model launched Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important […]

CellOPTIQ

Clyde Launches New Contractility Service – CellOPTIQ®-X

Posted on Leave a commentPosted in news

NEWHOUSE – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in animal requirements Accurate prediction of the human response Reduction in later stage attrition Heart cell […]

Alan Johnston

Clyde Appoints New Chair

Posted on Leave a commentPosted in news

Clyde Biosciences is delighted to announce the appointment of Alan Johnston to the post of Chair. Alan brings a wealth of CRO experience to Clyde. He spent some 30 years with Inveresk Research (subsequently Charles River Laboratories) in Edinburgh, Alan had several Senior Management posts within Inversek and had responsibility for Commercial staff. He is now Trustee […]

Clyde Biosciences

Clyde Biosciences Closes Series ‘A’ Investment

Posted on Leave a commentPosted in news

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.   Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. Clyde Biosciences, a spin-out company from the University of Glasgow, […]